Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFMO and Celecoxib with Cyclophosphamide/Topotecan in Relapsed/Refractory Neuroblastoma
NCT02030964Phase 1Completed
- Sponsor
- New Advances in Neuroblastoma Therapy
- Start
- Jan 2014
- Primary completion
- Dec 2023
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of eflornithine in neuroblastoma, sponsored by New Advances in Neuroblastoma Therapy. Primary endpoint: Adverse Events at 1 year. Started Jan 2014; status: completed.
02
Drugs
eflornithine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02030964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030964.